Relmada TherapeuticsRLMD
RLMD
About: Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Employees: 17
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
7.22% less ownership
Funds ownership: 27.84% [Q4 2024] → 20.61% (-7.22%) [Q1 2025]
8% less funds holding
Funds holding: 48 [Q4 2024] → 44 (-4) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
62% less capital invested
Capital invested by funds: $4.36M [Q4 2024] → $1.68M (-$2.68M) [Q1 2025]
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
Research analyst outlook
We haven’t received any recent analyst ratings for RLMD.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB).
Neutral
GlobeNewsWire
3 weeks ago
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative
Neutral
GlobeNewsWire
1 month ago
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S.
Neutral
Seeking Alpha
2 months ago
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Yair Lotan - Chief, Urology and Oncology Conference Call Participants Uy Ear - Mizuho Securities Matt Barcus - Jefferies Operator Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call.
Neutral
GlobeNewsWire
2 months ago
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients)
Neutral
GlobeNewsWire
2 months ago
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Neutral
GlobeNewsWire
3 months ago
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*
Neutral
GlobeNewsWire
3 months ago
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025
Neutral
GlobeNewsWire
3 months ago
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader (KOL) event on Monday, April 28, 2025 at 4:30 PM ET.
Neutral
GlobeNewsWire
3 months ago
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas.
Charts implemented using Lightweight Charts™